Top Markets
Coin of the day
Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS
Rank in Stocks #33562
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Share Price
$0.11989842
Market Cap
$7.42M
Change (1 day)
6.25%
Change (1 year)
179.27%
Country
AU
Trade Vectus Biosystems Limited (VBS)

Category

Earnings for Vectus Biosystems Limited (VBS)
Earnings in 2026 TTM: 0
According to Vectus Biosystems Limited latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Vectus Biosystems Limited from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE